Martina Deckert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3577295/publications.pdf

Version: 2024-02-01

111 papers	8,189 citations	94433 37 h-index	49909 87 g-index
115 all docs	115 docs citations	115 times ranked	11100 citing authors

#	Article	IF	Citations
1	Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases. Neuro-Oncology, 2022, 24, 1331-1340.	1.2	17
2	The process of somatic hypermutation increases polyreactivity for central nervous system antigens in primary central nervous system lymphoma. Haematologica, 2021, 106, 708-717.	3.5	14
3	The deubiquitinase OTUB1 augments NF-Î°B-dependent immune responses in dendritic cells in infection and inflammation by stabilizing UBC13. Cellular and Molecular Immunology, 2021, 18, 1512-1527.	10.5	40
4	OTUB1 prevents lethal hepatocyte necroptosis through stabilization of c-IAP1 during murine liver inflammation. Cell Death and Differentiation, 2021, 28, 2257-2275.	11.2	27
5	Treatment patterns and disease course of previously untreated Primary Central Nervous System Lymphoma: Feasibility of MTXâ€based regimens in clinical routine. European Journal of Haematology, 2021, 107, 202-210.	2.2	4
6	CD8 T cellâ€“Derived Perforin and TNF-Î± Are Crucial Mediators of Neuronal Destruction in Experimental Autoimmune Enteric Ganglionitis. American Journal of Pathology, 2021, 191, 1064-1076.	3.8	4
7	Clinical Characteristics and Magnetic Resonance Imagingâ€“Based Prediction of the KLF4 Mutation in Meningioma. World Neurosurgery, 2021, 154, e665-e670.	1.3	3
8	Novel Form of Congenital Myopathy Caused by Biallelic Mutations in Uncoordinated Mutant Number-45 Myosin Chaperone B. , 2021, 52, .		0
9	NIMG-27. REGORAFENIB RESPONSE ASSESSMENT USING FET PET IN PATIENTS WITH PROGRESSIVE GLIOMA. Neuro-Oncology, 2021, 23, vi134-vi134.	1.2	0
10	NIMG-20. DIFFERENTIATION OF TREATMENT-RELATED CHANGES FROM TUMOR PROGRESSION FOLLOWING BRACHYTHERAPY IN PATIENTS WITH WHO II AND III GLIOMAS USING FET PET. Neuro-Oncology, 2021, 23, vi132-vi132.	1.2	0
11	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System. Cancers, 2021, 13, 6334.	3.7	8
12	Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: response, progression, and pseudoprogression. Neuro-Oncology, 2020, 22, 17-30.	1.2	94
13	A tissueâ€specific screen of ceramide expression in aged mice identifies ceramide synthaseâ€1 and ceramide synthaseâ€5 as potential regulators of fiber size and strength in skeletal muscle. Aging Cell, 2020, 19, e13049.	6.7	18
14	Twenty-year follow-up of a pilot/phase II trial on the Bonn protocol for primary CNS lymphoma. Neurology, 2020, 95, e3138-e3144.	1.1	18
15	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy. Journal of Molecular Diagnostics, 2020, 22, 1300-1307.	2.8	9
16	A Multiplex Assay for the Stratification of Patients with Primary Central Nervous System Lymphoma Using Targeted Mass Spectrometry. Cancers, 2020, 12, 1732.	3.7	5
17	Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine. Case Reports in Oncology, 2020, 13, 35-42.	0.7	6
18	CXCR4-Targeted PET Imaging of Central Nervous System B-Cell Lymphoma. Journal of Nuclear Medicine, 2020, 61, 1765-1771.	5.0	34

#	Article	IF	Citations
19	KLF4K409Qâ€“mutated meningiomas show enhanced hypoxia signaling and respond to mTORC1 inhibitor treatment. Acta Neuropathologica Communications, 2020, 8, 41.	5.2	25
20	Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF. Cancer Immunology Research, 2019, 7, 1910-1927.	3.4	74
21	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. Acta Neuropathologica Communications, 2019, 7, 163.	5.2	37
22	TLR signals license CD8 TÂcells to destroy oligodendrocytes expressing an antigen shared with a Listeria pathogen. European Journal of Immunology, 2019, 49, 413-427.	2.9	5
23	<scp>OTUB</scp> 1 inhibits <scp>CNS</scp> autoimmunity by preventing <scp>IFN</scp> â€Îłâ€induced hyperactivation of astrocytes. EMBO Journal, 2019, 38, .	7.8	31
24	CBMT-25. THE KLF4K409Q MUTATION IN MENINGIOMA IMPAIRS HIF-1Îą DEGRADATION AND CAN BE HARNESSED FOR TARGETED THERAPY. Neuro-Oncology, 2019, 21, vi38-vi38.	1.2	0
25	Bi-allelic mutations in uncoordinated mutant number-45 myosin chaperone B are a cause for congenital myopathy. Acta Neuropathologica Communications, 2019, 7, 211.	5.2	15
26	Enteric Murine Ganglionitis Induced by Autoimmune CD8 T Cells Mimics Human Gastrointestinal Dysmotility. American Journal of Pathology, 2019, 189, 540-551.	3.8	7
27	Arrayâ€based profiling of the lymphoma cell DNA methylome does not unequivocally distinguish primary lymphomas of the central nervous system from nonâ€CNS diffuse large Bâ€cell lymphomas. Genes Chromosomes and Cancer, 2019, 58, 66-69.	2.8	10
28	Lymphome des Zentralnervensystems. , 2019, , 851-859.		0
29	CXCR4-Targeted Positron Emission Tomography Imaging of Central Nervous System B-Cell Lymphoma. Blood, 2019, 134, 2900-2900.	1.4	1
30	Long-Time Course of Idiopathic Small Fiber Neuropathy. European Neurology, 2018, 79, 161-165.	1.4	13
31	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	27.8	1,872
32	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. Acta Neuropathologica, 2018, 136, 273-291.	7.7	190
33	ITIH5 induces a shift in TGFâ€Î˛2 superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death. Molecular Carcinogenesis, 2018, 57, 167-181.	2.7	21
34	FET PET in Primary Central Nervous System Vasculitis. Clinical Nuclear Medicine, 2018, 43, e322-e323.	1.3	7
35	The Diagnosis and Treatment of Primary CNS Lymphoma. Deutsches Ärzteblatt International, 2018, 115, 419-426.	0.9	46
36	Dabrafenib Treatment in a Patient with an Epithelioid Glioblastoma and BRAF V600E Mutation. International Journal of Molecular Sciences, 2018, 19, 1090.	4.1	34

#	Article	IF	Citations
37	Distinct transcriptomic changes in E14.5 mouse skeletal muscle lacking RYR1 or Cav1.1 converge at E18.5. PLoS ONE, 2018, 13, e0194428.	2.5	18
38	Beyond the 3â€²UTR binding-microRNA-induced protein truncation via DNA binding. Oncotarget, 2018, 9, 32855-32867.	1.8	17
39	Lymphocyte antigens targetable by monoclonal antibodies in non-systemic vasculitic neuropathy. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 756-760.	1.9	8
40	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematology,the, 2017, 4, e510-e523.	4.6	258
41	Toll-Like Receptor 2, Toll-Like Receptor 4, Myeloid Differentiation Response Gene 88, and Tollâ€“IL-1 Receptor Domain-Containing Adaptor-Inducing Interferon-Î³ (TRIF) Selectively Regulate Susceptibility of P0106-125-Induced Murine Experimental Autoimmune Neuritis. American Journal of Pathology, 2017, 187, 42-54.	3.8	4
42	Proteomic changes in cerebrospinal fluid from primary central nervous system lymphoma patients are associated with protein ectodomain shedding. Oncotarget, 2017, 8, 110118-110132.	1.8	9
43	Gene profiling of embryonic skeletal muscle lacking type I ryanodine receptor Ca2+ release channel. Scientific Reports, 2016, 6, 20050.	3.3	13
44	Endothelial cellâ€derived angiopoietinâ€2 is a therapeutic target in treatmentâ€naive and bevacizumabâ€resistant glioblastoma. EMBO Molecular Medicine, 2016, 8, 39-57.	6.9	140
45	Absence of Lymphatic Vessels in PCNSL May Contribute to Confinement of Tumor Cells to the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2016, 75, 499-502.	1.7	3
46	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematology,the, 2016, 3, e217-e227.	4.6	442
47	High-dose chemotherapy with autologous haemopoietic stem cell transplantation for newly diagnosed primary CNS lymphoma: a prospective, single-arm, phase 2 trial. Lancet Haematology,the, 2016, 3, e388-e397.	4.6	128
48	Effects on Survival and Neurocognitive Functions of Whole-Brain Radiotherapy (WBRT) and Autologous Stem Cell Transplantation (ASCT) as Consolidation Options after High-Dose Methotrexate-Based Chemoimmunotherapy in Patients with Newly Diagnosed Primary CNS Lymphoma (PCNSL): Results of the Second Randomization of the IELSG32 Trial. Blood, 2016, 128, 511-511.	1.4	13
49	Endogenous Il10 Alleviates the Systemic Antiviral Cellular Immune Response and T Cellâ€“Mediated Immunopathology in Select Organs of Acutely LCMV-Infected Mice. American Journal of Pathology, 2015, 185, 3025-3038.	3.8	5
50	Protective dendritic cell responses against listeriosis induced by the short form of the deubiquitinating enzyme CYLD are inhibited by fullâ€length CYLD. European Journal of Immunology, 2015, 45, 1366-1376.	2.9	5
51	A20 expression in dendritic cells protects mice from LPSâ€induced mortality. European Journal of Immunology, 2015, 45, 818-828.	2.9	28
52	Primary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteins. Journal of Immunology, 2015, 195, 1312-1319.	0.8	37
53	Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology. Lancet Oncology, The, 2015, 16, e322-e332.	10.7	340
54	Stereotactic interstitial brachytherapy for the treatment of oligodendroglial brain tumors. Strahlentherapie Und Onkologie, 2015, 191, 936-944.	2.0	5

#	Article	IF	Citations
55	Response to Comment on â€œPrimary Central Nervous System (CNS) Lymphoma B Cell Receptors Recognize CNS Proteinsâ€. Journal of Immunology, 2015, 195, 4550-4551.	0.8	0
56	Immunoglobulin Repertoire of Primary Lymphomas of the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2014, 73, 1116-1125.	1.7	23
57	Costimulatory Molecule CD40 Is Essential for Myelin Protein 0 Peptide 106â€“125â€“Induced Experimental Autoimmune Neuritis in Mice. Journal of Neuropathology and Experimental Neurology, 2014, 73, 454-466.	1.7	4
58	Systems biology of primary CNS lymphoma: from genetic aberrations to modeling in mice. Acta Neuropathologica, 2014, 127, 175-188.	7.7	58
59	IL-10, IL-4, and STAT6 Promote an M2 Milieu Required for Termination of P0106-125-Induced Murine Experimental Autoimmune Neuritis. American Journal of Pathology, 2014, 184, 2627-2640.	3.8	20
60	Primary lymphoma of the central nervous systemâ€”a diagnostic challenge. Hematological Oncology, 2014, 32, 57-67.	1.7	52
61	Astrocytic A20 ameliorates experimental autoimmune encephalomyelitis by inhibiting NF-ÎºB- and STAT1-dependent chemokine production in astrocytes. Acta Neuropathologica, 2013, 126, 711-724.	7.7	73
62	Astrocytic <scp>F</scp>as ligand expression is required to induce <scp>T</scp>â€cell apoptosis and recovery from experimental autoimmune encephalomyelitis. European Journal of Immunology, 2013, 43, 115-124.	2.9	47
63	Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas. Acta Neuropathologica, 2013, 126, 603-605.	7.7	64
64	Solitary Plasmacytoma Presenting as an Intramedullary Mass of the Cervical Cord. Journal of Neurological Surgery, Part A: Central European Neurosurgery, 2013, 74, e13-e17.	0.8	3
65	CYLD Enhances Severe Listeriosis by Impairing IL-6/STAT3-Dependent Fibrin Production. PLoS Pathogens, 2013, 9, e1003455.	4.7	25
66	Listeriosis in pregnancy: case report and retrospective study. Journal of Maternal-Fetal and Neonatal Medicine, 2013, 26, 321-323.	1.5	8
67	Mechanisms of Intracerebral Lymphoma Growth Delineated in a Syngeneic Mouse Model of Central Nervous System Lymphoma. Journal of Neuropathology and Experimental Neurology, 2013, 72, 325-336.	1.7	10
68	Toll-Like Receptors Promote Inflammation in Idiopathic Inflammatory Myopathies. Journal of Neuropathology and Experimental Neurology, 2012, 71, 855-867.	1.7	35
69	Genes regulating the B cell receptor pathway are recurrently mutated in primary central nervous system lymphoma. Acta Neuropathologica, 2012, 124, 905-906.	7.7	63
70	Oligodendrocytes Enforce Immune Tolerance of the Uninfected Brain by Purging the Peripheral Repertoire of Autoreactive CD8+ T Cells. Immunity, 2012, 37, 134-146.	14.3	32
71	Neuronal gp130 Expression Is Crucial to Prevent Neuronal Loss, Hyperinflammation, and Lethal Course of Murine Toxoplasma Encephalitis. American Journal of Pathology, 2012, 181, 163-173.	3.8	37
72	Papillary tumors of the pineal region: a novel therapeutic optionâ€”stereotactic 125iodine brachytherapy. Journal of Neuro-Oncology, 2012, 109, 99-104.	2.9	10

#	Article	IF	Citations
73	Current strategies in the diagnosis of diffuse large Bâ€cell lymphoma of the central nervous system. British Journal of Haematology, 2012, 156, 421-432.	2.5	77
74	Sequential High Dose Immuno-Chemotherapy Followed by Autologous Peripheral Blood Stem Cell Transplantation for Patients with Untreated Primary Central Nervous System Lymphoma - a Multicentre Study by the Collaborative PCNSL Study Group Freiburg. Blood, 2012, 120, 302-302.	1.4	17
75	Intracranial Ependymoma: Long-Term Results in a Series of 21 Patients Treated with Stereotactic 125Iodine Brachytherapy. PLoS ONE, 2012, 7, e47266.	2.5	4
76	Infektionen des ZNS. , 2012, , 303-330.		0
77	An unusual case of optic neuritis. Journal of the Neurological Sciences, 2011, 304, 138-141.	0.6	2
78	Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood, 2011, 117, 3140-3146.	1.4	284
79	Gp130-Dependent Astrocytic Survival Is Critical for the Control of Autoimmune Central Nervous System Inflammation. Journal of Immunology, 2011, 186, 6521-6531.	0.8	105
80	Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma. Acta Neuropathologica, 2011, 122, 791-792.	7.7	151
81	Hypertrophy of the lumbar ligamentum flavum is associated with inflammation-related TGF-Î² expression. Acta Neurochirurgica, 2011, 153, 134-141.	1.7	53
82	Modern concepts in the biology, diagnosis, differential diagnosis and treatment of primary central nervous system lymphoma. Leukemia, 2011, 25, 1797-1807.	7.2	157
83	Mutations of CARD11 but not TNFAIP3 may activate the NF-ÎºB pathway in primary CNS lymphoma. Acta Neuropathologica, 2010, 120, 529-535.	7.7	86
84	Dual role of B cells with accelerated onset but reduced disease activity in P0106â€“125-induced experimental autoimmune neuritis of IgH0/0 mice. Acta Neuropathologica, 2010, 120, 667-681.	7.7	11
85	Diagnosis of leptomeningeal disease in diffuse large Bâ€cell lymphomas of the central nervous system by flow cytometry and cytopathology. European Journal of Haematology, 2010, 85, 520-528.	2.2	68
86	ProtectiveToxoplasma gondii-Specific T-Cell Responses Require T-Cell-Specific Expression of Protein Kinase C-Theta. Infection and Immunity, 2010, 78, 3454-3464.	2.2	14
87	Somatic mutations altering Tyr641 of EZH2 are rare in primary central nervous system lymphoma. Leukemia and Lymphoma, 2010, 51, 2135-2136.	1.3	10
88	Listeria monocytogenes (delta-actA mutant) infection in tumor necrosis factor receptor p55-deficient neonatal mice. Microbial Pathogenesis, 2010, 49, 186-195.	2.9	6
89	Array-based DNA methylation profiling of primary lymphomas of the central nervous system. BMC Cancer, 2009, 9, 455.	2.6	30
90	Primary lymphoma of the central nervous system: just DLBCL or not?. Blood, 2009, 113, 7-10.	1.4	69

#	Article	IF	Citations
91	Preferential Expression of Truncated Isoforms of FOXP1 in Primary Central Nervous System Lymphoma. Journal of Neuropathology and Experimental Neurology, 2009, 68, 972-976.	1.7	11
92	CD4 T Cells Mediate Axonal Damage and Spinal Cord Motor Neuron Apoptosis in Murine P0106â€“125-Induced Experimental Autoimmune Neuritis. American Journal of Pathology, 2008, 173, 93-105.	3.8	19
93	Recurrent Inactivation of the PRDM1 Gene in Primary Central Nervous System Lymphoma. Journal of Neuropathology and Experimental Neurology, 2008, 67, 720-727.	1.7	51
94	Molecular Mimicry between Neurons and an Intracerebral Pathogen Induces a CD8 T Cell-Mediated Autoimmune Disease. Journal of Immunology, 2008, 180, 8421-8433.	0.8	24
95	Transcriptional Profiling of the Nuclear Factor-ÎºB Pathway Identifies a Subgroup of Primary Lymphoma of the Central Nervous System With Low BCL10 Expression. Journal of Neuropathology and Experimental Neurology, 2007, 66, 230-237.	1.7	44
96	Interleukin-1 Receptor Type 1 Is Essential for Control of Cerebral but Not Systemic Listeriosis. American Journal of Pathology, 2007, 170, 990-1002.	3.8	16
97	Expression pattern and cellular sources of chemokines in primary central nervous system lymphoma. Acta Neuropathologica, 2007, 114, 271-276.	7.7	61
98	Chromosomal Translocations Fusing theBCL6Gene to Different Partner Loci Are Recurrent in Primary Central Nervous System Lymphoma and May Be Associated With Aberrant Somatic Hypermutation or Defective Class Switch Recombination. Journal of Neuropathology and Experimental Neurology, 2006, 65, 776-782.	1.7	53
99	Regulation of the Inflammatory Response to Staphylococcus aureus-Induced Brain Abscess by Interleukin-10. Journal of Neuropathology and Experimental Neurology, 2005, 64, 1046-1057.	1.7	11
100	Absence of Immunoglobulin Class Switch in Primary Lymphomas of the Central Nervous System. American Journal of Pathology, 2005, 166, 1773-1779.	3.8	47
101	VH gene analysis of primary CNS lymphomas. Journal of the Neurological Sciences, 2005, 228, 143-147.	0.6	26
102	T Cellâ€specific Inactivation of the Interleukin 10 Gene in Mice Results in Enhanced T Cell Responses but Normal Innate Responses to Lipopolysaccharide or Skin Irritation. Journal of Experimental Medicine, 2004, 200, 1289-1297.	8.5	283
103	Absence of simian virus 40 DNA sequences in primary central nervous system lymphoma in HIV-negative patients. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2004, 444, 436-438.	2.8	20
104	Primary diffuse large B-cell lymphomas of the central nervous system are targeted by aberrant somatic hypermutation. Blood, 2004, 103, 1869-1875.	1.4	164
105	Molecular Characterization of BCL6 Breakpoints in Primary Diffuse Large Bâ€cell Lymphomas of the Central Nervous System Identifies GAPD as Novel Translocation Partner. Brain Pathology, 2003, 13, 534-538.	4.1	29
106	Interphase Cytogenetic Analysis of Lymphoma-Associated Chromosomal Breakpoints in Primary Diffuse Large B-Cell Lymphomas of the Central Nervous System. Journal of Neuropathology and Experimental Neurology, 2002, 61, 926-933.	1.7	70
107	Destruction of neurons by cytotoxic T cells: A new pathogenic mechanism in rasmussen's encephalitis. Annals of Neurology, 2002, 51, 311-318.	5.3	353
108	Endogenous Interleukin-10 Is Required for Prevention of a Hyperinflammatory Intracerebral Immune Response in Listeria monocytogenes Meningoencephalitis. Infection and Immunity, 2001, 69, 4561-4571.	2.2	72

#	Article	IF	Citations
109	Human herpes virus-8 is not associated with primary central nervous system lymphoma in HIV-negative patients. Acta Neuropathologica, 2001, 102, 489-495.	7.7	19
110	Clonal Expansions of Cd8+ T Cells Dominate the T Cell Infiltrate in Active Multiple Sclerosis Lesions as Shown by Micromanipulation and Single Cell Polymerase Chain Reaction. Journal of Experimental Medicine, 2000, 192, 393-404.	8.5	842
111	Determination of the proliferative potential of human brain tumors using the monoclonal antibody Ki-67. Journal of Cancer Research and Clinical Oncology, 1989, 115, 179-188.	2.5	93